AngioDynamics (NASDAQ:ANGO) Sets New 52-Week High Following Analyst Upgrade

AngioDynamics, Inc. (NASDAQ:ANGO) hit a new 52-week high during trading on Thursday after HC Wainwright raised their price target on the stock from $16.00 to $19.00. HC Wainwright currently has a buy rating on the stock. AngioDynamics traded as high as $14.80 and last traded at $14.47, with a volume of 1374802 shares traded. The stock had previously closed at $13.00.

ANGO has been the topic of a number of other research reports. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Canaccord Genuity Group increased their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Finally, Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, AngioDynamics presently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

Key Stories Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported Q4 adjusted EPS of -$0.07, better than the -$0.11 estimate, while revenue of $86.61 million also topped forecasts. Article Title
• Positive Sentiment: Management said fiscal 2026 was a record year, with continued execution driving Med Tech growth and full-year profitability, which can support a stronger investor narrative. Article Title
• Positive Sentiment: AngioDynamics raised its fiscal 2027 revenue outlook to $336 million-$341 million, above consensus, signaling confidence in continued top-line growth. Article Title
• Positive Sentiment: HC Wainwright increased its price target on ANGO from $16 to $19 and reiterated a buy rating, implying further upside if execution continues. Article Title
• Neutral Sentiment: Analysts now broadly expect AngioDynamics to keep improving, but profitability remains negative and the company’s FY2027 EPS guidance is still below consensus, so investors may want to watch whether margin gains continue.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Farther Finance Advisors LLC boosted its stake in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of AngioDynamics during the fourth quarter valued at approximately $27,000. State of Wyoming bought a new position in shares of AngioDynamics during the second quarter valued at approximately $31,000. Russell Investments Group Ltd. increased its stake in shares of AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 4,268 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Stock Performance

The business has a 50-day moving average price of $12.14 and a 200 day moving average price of $11.33. The stock has a market capitalization of $597.90 million, a P/E ratio of -16.63 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The company had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts forecast that AngioDynamics, Inc. will post -0.26 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.